Overview
This study invastigates the effect of icosapent ethyl in patients with aortic valve stenosis.
Eligibility
Inclusion Criteria:
- Age > 50 years
- Mild to moderate AVS
Exclusion Criteria:
- Bicuspid aortic valve
- History of chest radiotherapy
- History of rheumatic fever
- Moderate to severe renal failure, defined as eGFR < 30 ml/min
- Hyperparathyroidism
- Paget's disease
- Diagnosis of (active) malignancy in last 5 years
- Anticipated or planned aortic valve surgery in the next 6 months
- Life expectancy <2 years
- Chronic atrial fibrillation
- Use of anticoagulant medication or dual antiplatelet therapy
- Known hypersensitivity to fish and/or shellfish
- Known hypersensitivity to soya
- Malabsorption syndrome and/or chronic diarrhea
- Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control [such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (condoms)] to avoid pregnancy for the entire study.
- Women who are pregnant or breastfeeding
- Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study